ImmunoPrecise Antibodies ...

NASDAQ: IPA · Real-Time Price · USD
3.03
0.40 (15.21%)
At close: Aug 22, 2025, 10:50 AM

ImmunoPrecise Antibodies Balance Sheet Statement

Financials in CAD. Fiscal year is May - April.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Apr 30, 2025 Apr 30, 2024 Apr 30, 2023 Apr 30, 2022 Apr 30, 2021
Cash & Equivalents
10.66M 3.46M 8.28M 29.96M 41.76M
Short-Term Investments
n/a n/a n/a n/a n/a
Long-Term Investments
n/a n/a 115K 142K 111K
Other Long-Term Assets
126K 561K 86K 82K 79K
Receivables
4.81M 4.07M 3.88M 3.41M 3.63M
Inventory
2.1M 2.14M 2.06M 1.61M 1.2M
Other Current Assets
n/a 414K 536K n/a 491K
Total Current Assets
18.75M 11.49M 16.79M 37.47M 48.86M
Property-Plant & Equipment
16.26M 16.7M 10.72M 3.71M 4.08M
Goodwill & Intangibles
9.3M 31.24M 50.1M 52.09M 13.84M
Total Long-Term Assets
25.69M 48.5M 61.02M 56.02M 18.1M
Total Assets
44.44M 59.99M 77.81M 93.49M 66.96M
Account Payables
5.28M 4.07M 2.48M 3.92M 1.34M
Deferred Revenue
1.09M n/a 977K 1.03M 1.11M
Short-Term Debt
n/a n/a n/a 1.31M n/a
Other Current Liabilities
314K 2.49M 2.32M 2.17M 1.94M
Total Current Liabilities
9.01M 8.12M 5.92M 9.26M 6.07M
Long-Term Debt
n/a n/a n/a n/a 1.53M
Other Long-Term Liabilities
n/a 5.83M 7.94M 8.48M n/a
Total Long-Term Liabilities
11.8M 17.94M 14.09M 8.95M 3.96M
Total Liabilities
20.82M 26.07M 20.01M 18.21M 10.04M
Total Debt
13.4M 13.68M 7.27M 2.55M 3.46M
Common Stock
136.37M 119.77M 117.47M 114.56M 80.1M
Retained Earnings
-128.79M -100.27M -73.09M -46.53M -29.82M
Comprehensive Income
3.22M 2.02M 2.63M -2.48M -687K
Shareholders Equity
23.63M 33.92M 57.8M 75.28M 56.92M
Total Investments
n/a n/a 115K 142K 111K